INSIGHTS ON CELL & GENE COMMERCIALIZATION ISSUES
-
Building A Fit-For-Purpose, Strategic Cell & Gene Production Facility
By employing flexible and sustainable design strategies and best practices, combined with contingency planning, cell and gene therapy companies can make building their own facilities a reality.
-
Best Practices For Reducing Variability Without Increasing Regulatory Burden
Explore why expectations grow along the curve and why understanding what's expected early on is important.
-
How Community Oncologists View CAR T-Cell Therapy Possibilities And Challenges
Learn how a partner with innovative solutions aimed at overcoming the barriers that limit the real-world impact of CAR T-cell therapy can make these advanced therapies more accessible and affordable.
-
2024’s Market Outlook For Cell & Gene Therapies
RSM is back for the third consecutive year to provide an outlook analysis of the cell and gene therapy market. This article discusses the 2024 state of the macroeconomy, its effects on cell and gene therapy companies, growing approval pipelines and approvals, funding factors, and the unique prospects for the market.
-
Discussing mRNA: Challenges And Opportunities For Scale-Out And Optimization
In a recent Cell & Gene Live event, experts explored challenges surrounding raw materials – both quality and supply – as well as the importance of achieving more efficient scale-out and turnaround times for mRNA production.
-
Pricing, Value, And Access of CGTs With The Dedham Group's Jennifer Klarer, M.Sc.Eng.
The Dedham Group's Jennifer Klarer, M.Sc.Eng., Partner and Head of Cell & Gene Therapy, joins Erin Harris on this episode of Cell & Gene: The Podcast for a deep dive into pricing and value for CGTs. Klarer shares a detailed breakdown of the most misunderstood aspects of cell and gene therapy pricing, value, and affordability. She details how manufacturers can get ahead of addressing time-to-treatment issues typically experienced at launch. They cover obtaining adequate investment dollars, and much more.
-
An Exploration Of ICIs In Cancer Therapy
This collection of frequently asked questions highlights the remarkable efficacy of immune checkpoint inhibitors (ICIs) and the projected growth of the global ICI market.
-
Pricing, Value, And Access of CGTs With The Dedham Group's Jennifer Klarer, M.Sc.Eng.
The Dedham Group's Jennifer Klarer, M.Sc.Eng., Partner and Head of Cell & Gene Therapy, joins Erin Harris on this episode of Cell & Gene: The Podcast for a deep dive into pricing and value for CGTs. Klarer shares a detailed breakdown of the most misunderstood aspects of cell and gene therapy pricing, value, and affordability. She details how manufacturers can get ahead of addressing time-to-treatment issues typically experienced at launch. They cover obtaining adequate investment dollars, and much more.
-
The Ins And Outs Of In-House Manufacturing: Building A Cell & Gene Production Facility
Deciding whether to bring manufacturing in-house or outsource it to a partner can be a daunting decision, particularly as market forces continue to put pressure on small biotechs.
-
Collaborating with the FDA: Dr. Peter Marks and Dr. Nicole Verdun Share Advice For Small And Emerging Biotechs
In this segment, Dr. Peter Marks and Dr. Nicole Verdun share their advice and best practices for small and emerging biotechs when working with the FDA.